New Study Compares Two Continuous Glucose Monitoring Sensors for Effectiveness and Satisfaction

NEW ROCHELLE, N.Y. - Sept. 18, 2014 - PRLog -- Simultaneous use of two popular continuous glucose monitoring (CGM) sensors revealed clear differences in their accuracy and in patient-rated treatment experiences, including ease of use, feelings of safety, and willingness to use the system in daily life. Results of a clinical trial comparing the Dexcom^® G4 and Enlite™ sensors are published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/). The article is published Open Access on the DTT  website (http://online.liebertpub.com/doi/full/10.1089/dia.2014.0238).

Viktorija Matuleviciene, MD and coauthors from University of Gothenburg and Statistiska Konsultgruppen (Gothenburg, Sweden), Jefferson Medical College of Thomas Jefferson University (Philadelphia, PA), NU-Hospital Organization (Uddevalla, Sweden), University of Washington (Seattle, WA), and Mills-Peninsula Health Services (San Mateo, CA) report that the Dexcom^® G4 System (Dexcom, Inc.) showed greater accuracy than the Enlite™ Guardian Real-Time System (Medtronic MiniMed, Inc.) when blood glucose levels were in the normal or hypoglycemic ranges.

Significantly more patients reported their experience with the Dexcom^® G4 as positive and said they preferred to use it in their daily lives, according to findings presented in the article “A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom^® G4 Sensor (Dexcom^® G4 System) and Enlite™ Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes (http://online.liebertpub.com/doi/full/10.1089/dia.2014.0238).”

“This investigator-initiated trial highlights the differences in performance of different continuous glucose monitors available in the marketplace,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver. “However, several other sensors (more accurate with single-digit MARD) are in development to improve the lives of people with diabetes. More accurate sensors are needed for developing the artificial pancreas.”

About the Journal
Diabetes Technology & Therapeutics (DTT) (http://www.liebertpub.com/dia) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) (http://www.liebertpub.com/dia) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) (http://www2.kenes.com/attd/pages/home.aspx) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher
Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) website.